CA1139667A - Galenical compositions - Google Patents
Galenical compositionsInfo
- Publication number
- CA1139667A CA1139667A CA000322853A CA322853A CA1139667A CA 1139667 A CA1139667 A CA 1139667A CA 000322853 A CA000322853 A CA 000322853A CA 322853 A CA322853 A CA 322853A CA 1139667 A CA1139667 A CA 1139667A
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- pharmaceutical composition
- weight
- cyclosporin
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
NEW GALENICAL COMPOSITIONS
Abstract of the Disclosure The present invention provides a pharmaceutical composition comprising a pharmacologically active mono-cyclic peptide and a carrier comprising at least one of the following components:-a) a non-ionic ester of a triglyceride and a polylakylene polyol, b) a saturated fatty acid triglyceride, and c) a mono- or di-glyceride having improved physical and absorption properties.
Abstract of the Disclosure The present invention provides a pharmaceutical composition comprising a pharmacologically active mono-cyclic peptide and a carrier comprising at least one of the following components:-a) a non-ionic ester of a triglyceride and a polylakylene polyol, b) a saturated fatty acid triglyceride, and c) a mono- or di-glyceride having improved physical and absorption properties.
Description
NEW GALENICAL COMPOSITIONS
' This invention relates to galenical compositions, particularly compositions containing a pharmacologically active mono-cyclic peptide.
Because of the hydrophobic and/or lipophilic charac ter of such peptides, pharmaceutical formulations thereof with conventional solid or liquid pharmaceutical excipients tend to have disadvantages. For example the peptide may not be satisfactorily absorbed, the co~position. may not be well tolerated, the composition,may not be sufficiently stable on storage e.g. against crystallizing-out of the peptide, and/or the concentration of the peptide capable of being solubilized,without crystallizing-out may be low, e.g. of the order of 3% or lower.
Problems of this nature arise not only with liquid formulations, but such solid forms such as solid ~, solu-tions", e.g.in the form of oral pellets, produced for example by melting a sol,id carrier/mixing in the active ingredient and allo~ing the mixture to solidify.
While there are many known proposals ~ alleviat~
or overcome problems of this type, it has been found after 9~
exhaustive trials that many of these proposals are inadequate in the area of the monocyclic peptides, in particular cyclosporins, with which the invention is concerned. It has, however, surprisingly been found that certain classes of glycerides used as carrier components do assist in alleviating these difficulties; in particular they, for example, may enable achievement of higher blood levels of active agent or avoid other problems such as instability.
The present invention accordingly provides a pharmaceutical composition comprising a cyclosporin as active.ingredient and carrier comprising at least one of the following components:-a) a trans-esterification product of a natural or hydrogenated vegetable oil triglyceride and a polyalkylene p~olyol;
b) a saturated fatty acid triglyceride, and c) a mono-or di-glyceride.
The compositions of the invention are particularly suitable for hydrophobic and/or lipophilic peptides which are insoluble or difficultly soluble in conventional pharmaceutical vehicles, in particular cyclosporins, including those having a basic ring structure as follows:-D
t 1 '7 ~:H3~ ~CH~
CH
CH ~ ~C H~
Cl~2 C~ 1 Cl~3 IC~ N--CH--CO--1~1 CH~ A . - N--CH2.
CO
~CH--CH2--1H 1. CO
CH3 ¦ I~l-CH~
¦ D ~ ~ O ~
OC--Ch--~--CO-CH--N--CO--CH--N--C--Cl1--N--CO----CH
. 1 CH3 H CH~ ~ CH3 C~
C~-~ Cl~ C--~ C~
wherein A is a bivalent moiety containing two amino acids llnked together.
A may be for example:-\C/
C (cyclos~orin A) HO~R)~C~(R) C~H3 3~1H CH3 CIH2 - N - C~ - CO - N--CH-CO-S~; ~ ~L) H3C~
H2C j cl~2 (dihydrocyclos-HO\R)~c\(~) I 3 . porin C) CU3 CH CH3 (OCIH -OH
- N - CH ~ CO - N - CH ~CO-(L) ..
CH ~ ~ ~ t1 ~C~c . i (cyclosporin D ) Ho~R)~C~ CHj / 3 Ct~3 ¦ CH
--1--C~ CO--N~ CO--k) I (L) CM~
II~,C~C
I (R) Ho.~RCk ~C~ CH3 CH3 CH3 I CH ( dihydrocyclos- -C0--N--CH--C0- porin D), or ~L) I (L) e t~ ~Cl~2 j ~( t1~ ~Ct~ \3 / H3 ~IN CH CO-- N-- CH--CO (iso-cyclosporin D ) l a h~) I (L) C~yclosporin A, dihydr~cyclosporin C and isocyclospor:Ln D are the preferred peptides.
11~9~
Component a) may be prepared in conventional manner, e.g. as described in U.S. Patent Specification No 3,288,824.
The ester may be a transesterification product of two molar parts of a natural oil, such as corn oil, almond oil, ground-nut oil, olive oil and/or palm oil, with one molar part of apolyethylene glycol of MW 200 to 800. Such esters are commer-cially available under the trade mark LABRAFI ~ (see Fiedler, Lexicon der Hilfstoffe, p. 320, 1971), from Etablissement Gattefossé, Boulogne-sur-Seine, France. Labrafil is a poly-oxyethylated kernel oil mixture, having a density of D20 =0.940-0.965, an acid number 2, an iodine number = 60-90, a saponification number = 145-175 and a hydrophilic-lipophilic balance (H.L.B.) = 4.
Component b~ may be obtained in conventional manner using, for example, fatty acids having a chain length of from 8 to 12 carbon atoms. Generally these glycerides will have an iodine number of less than 2. Examples of such glycerides are commercially available under the trade mark MIGLYOL~
from Dynamit Nobel Witten/Ruhr Germany, especially Miglyol 812, or MYRITO ~ 318 from Henkel Dusseldorf, Germany.
Component c) is preferably one of the mono- or di-glycerides approved for pharmaceutical use, e.g. a mono~ or di-(C16-C20) fatty acid glyceride, e.g. of stearlc acid or especially of oleic acid. Preferably component c) is glycerol mono-oleate (Monooleinum-Pharmacopoea ~elvetica Sixth Edition).
Naturally when the components a), b) and/or c) present are solid, these should be chosen such that they can .~
D
~13g~
be melted at temperatures at which the peptide is stable.
Such components include, for example, glycerol mono-stearate and glycerol di-stearate.
The preferred total concentration of component a) and/or component b) and/or component c) present in the pharmaceutical compositions according to the invention, as well as the weight ratio of individual components when two or more of these are present, will natuxally depend, ~ , on the particular component(s) used, and in partlcular on the solvent/solubilizing effect thereof, the particular mono-cyclic peptide used, the concentration of mono-cyclic peptide desired in the final composition and the solvent/solubilizing effect of any further pharmaceu-tical excipients present. In general the preferred welght ratio of component a), b) and/or c) to peptide is 10 parts ln total of the component (or components) to 0.2 to 10 parts of peptide,or more preferably 1 to 10 parts by weight of peptide, and conveniently from 1 to 7 parts by weight of peptide.
When components a) and b) are present, without component c), the weight ratio of component a) to com-ponent b) may be, e.gl from 1:1 to 1:2.
When component c) is present with component a) or b), the weight ratio of component c) to component a) or b) may be, e.g./ from 2:1 to 1:2.
When components a), b) and c) are all present, conven-9~
_ 7 - 100-4983 lently they are present in a weight ratlo of about 1:1:1.
The pharmaceutical compositions of the invention may be made by mixing a pharmacologically active mono-cyclic peptide with the liquid carrier comprising component a) and/or b) and/or c) as deflned above.If the o~nent a), ,, . .: , b) or c) is solid~temperatures up to about 70C may be used, to produce a liquid melt in which the active agent may be dissolved in. The composition may be cooled and then, for example, ground.
The pharmaceutical compositions may be formulated in conventional manner, if desired with further pharma-ceutlcal excipients, into forms suitable for oral or parenteral administration. Preferably they are in liquid form.
Examples of preferred compositions are:
a) Solutions for drlnking, e.g. Example 1 herelnafter, b) Emulsions for drinking, c) Injection solutions, e.g. Examples 2 and 4 hereinafter, d) Solutions contained in capsules, e.g. Example 6 herein-after, e) Pellets for oral administration.
The modes of administratlon are preferably intra-muscular and subcutaneous administration or more preferably oral administration. In particular when component b) is present, the pharmaceutical composition is preferably used for parenteral administration.
i~9~, The pharmaceutical compositions acco'rding to the invention may be formulated with or without further exi-pients.
In particular solubilizing a~ents and solvents may be present in a concentration of up to 60~ of the total com-position, if desired, in order to attain a satisfactory concentration of peptide.
i) Ethanol may be used as a further solubilizing agent/
solvent, particularly when the component a), b) or c) pre-sent is in solid form. The ethanol content by weight maybe''for example 2 to 5~ for parenteral compositions and 1 to 20% for oral compositions, calculated on the total compo-sitio~. ' ii) For a parenteral composltion, an alternative further solubilizin~ agent/solvent is a benzoic acid benzyl ester.
This may be present ~t from 5 to~40%~of by weight of the total composition.
iii) A vegetable oil, such as olive oil or co~n oil, may be present in both oral and parehteral compositions as a vehicle. The vegetable oil content by weight may be for example from 35 to 60 %, calculated on the total composition.
iv) For emulsions for drinking, preferably agent a) and/or c) as defined above is present as well as a lecithin such as soya lecithin. Such emulsions may contain from 20% to 80% by weight water and contain eth~anol as a solubilizing agent / solvent.
..._._ ~
v) For oral pellets, it is preferred to use a solid or semi-solid component a), b) or c), espec:ially component c). Colloidal silicic acid, sugar, and microc~ystalline cellulose are sultable excipients.
The properties of the compositions according to the invention may be determined in conventional manner. The sta bility of solutions particularly against crystallization-out of the active agent may be determined using known tests.
Tolerability of injection forms may be de~ermined by ob-serving the extent of bleeding and inflammations after in-jection, e.g. into thighs of rabbits and rhesus monkeys, andthe time taken for these to heal, as well as by using other usual tolerability tests.
The ~sorption of the pharmacologically active pep-tide, e.g rapid onset of a satisfactory concentration of the peptide in the blood, and a high total absorption of the peptide over 24 hours, is indicated in standard tests.
In one test a pharmaceutical composition according to the invention is administered to rabbits, rats, dogs or rhesus monkeys orally, intramuscularly or subcutaneously, at a dose of from 2 to 600 mg/kg animal body weight of active peptide. Blood serum samples and urine samples are taken at regular intervals thereafter, e.g. every hour, and are analysed for the concentration of peptide therein in con-ventional manner.
For example the pharmacological activity in a sample may be ascertained in conventional manner according to known tests. In the case of cyclosporin A the effect of the peptide present in inhibiting lymphocyte proliferation may be ascer-tained. ~'hus the blood serum is collected at regular inter-vals after administration, and is added at a concentration of from 0.3 to 10~ to a mouse in vitro spleen oell--suspension in whlch lymphocyte proliferation is induced by Concavalin A over a 72 hour culture period. 3H-thymidine is then added and the thymidine incorporation after r~ 24 hours ls mea8ured to indicate the lymphocyte proliferation.
If desired,the peptide may be administered in radio-active form. For example in the case of the cyclosporins, in one experiment 100 mg of H-labelled cyclospor~n A (pre-pared hy cultivation of the known strain Tolypocladium inflatum Gams NRRL 8044 in the presence of methionine marked wlth tritlum in the SCH3 group thereofJ contained in a phar-maceutical composition according to the invention in the form of a drinking solution, or in a capsule,is administered perorally, or in the form of an injection solution is admini-stered intramuscularly, to male bea~le dogs. Blood samplesare obtained from each dog every 5 minutes after admini-"
11;~9~
_ 11_ 100-4983 stration up to 1 hour after administration and thereafter every hour thereafter up to 8 hours after ad~inistration.
The urine is collected also. Determination of the radio-activity in the blood and in the urine indicates the peptide absorption.
The amount of peptide to be administered in the pharmaceutical compositions according to the invention wlll naturally depend upon the mode of administration, the effect desired and the condition to be treated.
In general the amount of peptiae to be administered in a pharmaceutical composition accoxding to invention will be of the same order to that administered by the same route in other pharmace~tical compositions.
In the case of the cyclosporins, the amounts to be 15 adm~nistered for a therapeutically effective amount are well-known, When using compositions according to the in-vention a dally dose of from about 3 mg/kg to about 50 mg/kg i~ indicated in order to treat chronic inflammations or to provoke an immunosuppressive effect.
The following examples illustrate the invention.
All temperatures are in degrees Centigrade.
11;~9~7 _ 12 - 100-4983 . .
EXAMPLE 1: Drink Solution ~ _ _ _ _ _ _ 200 mg of cyclosporin A are dissolved on stirring in 1 ml of a mixture of Labrafil M 1944 CS and ethanol (parts by weight 40:15) at 25. 0.4 ml of olive oil or corn oil are added. The resultant mixture is filtered and filled into a small vial.
The final solution contains for every 10 parts by weight of Labrafil; 3 parts by weight of cyclosporin A, 3 parts by weight of ethanol and 5 parts by weight of olive 10 oil or corn oil.
EXAMPLE 2: Parenteral forms for i.m. and s.c.administr~tion 100 mg of cyclosporin A are dissolved on stirring in a mixture of 40 mg ethanol and 0.5 ml Miglyol 812 at 25C~ The mixture is finally made up to 1 ml with Miglyol 15 812 and filled under sterile conditions into ar~ ampoule.
The final solution contains for every 10 part:s by weight of Miglyol 812, 1 part by weight of cyclosporin A.
EXA~IPLE 3: Parenteral forms for i.m. and s.c. administratinn _ 100 mg of cyclosporin A are dissolved on stirring 20 in a mixtuxe of 40 mg ethanol, 100 mg Labrafil M 1944 CS
and 200 mg Miglyol 812 at 25.~ The resulting mixture is made up to 1 ml with olive oil and iilled under sterile conditions into an ampoule.
The final solution contains for every 10 parts by 25 weight of Miglyol 812, 5 part~ ky weight each of cyclos-porin A and Labrafil and 25 parts by weight of olive oil.
. .
il;~9~
_ 13 _ 100-49B3 EXAMPLE 4: Parenteral form for i.m.and s.c. admlnistration 200 mg of cyclosporin A are dissolved in a mixture of 400 mg benzoic acid benzyl ester and 0.3 ml Miglyol 812 at 25. The resultant mixture is made up to 1 ml with Miglyol 812 and fllled under sterile conditions-into an ampoule.
The final solution contains for every 10 parts by weight of Miglyol 812, 6 parts by weight of cyclosporin A.
EX~MPLE 5: Parenter_1 form for i.m. and_s.c.ad~inistratio_ 200 mg of cyclosporin A are dissolved on stirring in a mixture of 50 mg ethanol, 300 mg Labrafil M 1944 CS and 0.3 ml' Miglyol 812 at 25. The resultant solutlon is made up to 1 ml with Miglyol 812 and filled under sterile condi-tions into an ampoule.
The final solution contains for every 10 part~ by weight of Miglyol 812, 7 parts by weight of Labrafil and 5 parts by weight of cyclosporin A.
EXAMPLE 6: Capsules for oral adm_nistration 200 mg of cyclosporin A are dissolved on stirring in a mixture of 600 mg glycerol mono-oleate and 30 mg ethanol at 30. The final solution is encapsulated in a soft gelatine capsule.
Ca~sules for oral administration 400 mg of cyclosporin A are dlssolved on stirring in 600 mg glycerol mono-oleate at 40, and encapsulated ln a soft gelatine capsule.
' This invention relates to galenical compositions, particularly compositions containing a pharmacologically active mono-cyclic peptide.
Because of the hydrophobic and/or lipophilic charac ter of such peptides, pharmaceutical formulations thereof with conventional solid or liquid pharmaceutical excipients tend to have disadvantages. For example the peptide may not be satisfactorily absorbed, the co~position. may not be well tolerated, the composition,may not be sufficiently stable on storage e.g. against crystallizing-out of the peptide, and/or the concentration of the peptide capable of being solubilized,without crystallizing-out may be low, e.g. of the order of 3% or lower.
Problems of this nature arise not only with liquid formulations, but such solid forms such as solid ~, solu-tions", e.g.in the form of oral pellets, produced for example by melting a sol,id carrier/mixing in the active ingredient and allo~ing the mixture to solidify.
While there are many known proposals ~ alleviat~
or overcome problems of this type, it has been found after 9~
exhaustive trials that many of these proposals are inadequate in the area of the monocyclic peptides, in particular cyclosporins, with which the invention is concerned. It has, however, surprisingly been found that certain classes of glycerides used as carrier components do assist in alleviating these difficulties; in particular they, for example, may enable achievement of higher blood levels of active agent or avoid other problems such as instability.
The present invention accordingly provides a pharmaceutical composition comprising a cyclosporin as active.ingredient and carrier comprising at least one of the following components:-a) a trans-esterification product of a natural or hydrogenated vegetable oil triglyceride and a polyalkylene p~olyol;
b) a saturated fatty acid triglyceride, and c) a mono-or di-glyceride.
The compositions of the invention are particularly suitable for hydrophobic and/or lipophilic peptides which are insoluble or difficultly soluble in conventional pharmaceutical vehicles, in particular cyclosporins, including those having a basic ring structure as follows:-D
t 1 '7 ~:H3~ ~CH~
CH
CH ~ ~C H~
Cl~2 C~ 1 Cl~3 IC~ N--CH--CO--1~1 CH~ A . - N--CH2.
CO
~CH--CH2--1H 1. CO
CH3 ¦ I~l-CH~
¦ D ~ ~ O ~
OC--Ch--~--CO-CH--N--CO--CH--N--C--Cl1--N--CO----CH
. 1 CH3 H CH~ ~ CH3 C~
C~-~ Cl~ C--~ C~
wherein A is a bivalent moiety containing two amino acids llnked together.
A may be for example:-\C/
C (cyclos~orin A) HO~R)~C~(R) C~H3 3~1H CH3 CIH2 - N - C~ - CO - N--CH-CO-S~; ~ ~L) H3C~
H2C j cl~2 (dihydrocyclos-HO\R)~c\(~) I 3 . porin C) CU3 CH CH3 (OCIH -OH
- N - CH ~ CO - N - CH ~CO-(L) ..
CH ~ ~ ~ t1 ~C~c . i (cyclosporin D ) Ho~R)~C~ CHj / 3 Ct~3 ¦ CH
--1--C~ CO--N~ CO--k) I (L) CM~
II~,C~C
I (R) Ho.~RCk ~C~ CH3 CH3 CH3 I CH ( dihydrocyclos- -C0--N--CH--C0- porin D), or ~L) I (L) e t~ ~Cl~2 j ~( t1~ ~Ct~ \3 / H3 ~IN CH CO-- N-- CH--CO (iso-cyclosporin D ) l a h~) I (L) C~yclosporin A, dihydr~cyclosporin C and isocyclospor:Ln D are the preferred peptides.
11~9~
Component a) may be prepared in conventional manner, e.g. as described in U.S. Patent Specification No 3,288,824.
The ester may be a transesterification product of two molar parts of a natural oil, such as corn oil, almond oil, ground-nut oil, olive oil and/or palm oil, with one molar part of apolyethylene glycol of MW 200 to 800. Such esters are commer-cially available under the trade mark LABRAFI ~ (see Fiedler, Lexicon der Hilfstoffe, p. 320, 1971), from Etablissement Gattefossé, Boulogne-sur-Seine, France. Labrafil is a poly-oxyethylated kernel oil mixture, having a density of D20 =0.940-0.965, an acid number 2, an iodine number = 60-90, a saponification number = 145-175 and a hydrophilic-lipophilic balance (H.L.B.) = 4.
Component b~ may be obtained in conventional manner using, for example, fatty acids having a chain length of from 8 to 12 carbon atoms. Generally these glycerides will have an iodine number of less than 2. Examples of such glycerides are commercially available under the trade mark MIGLYOL~
from Dynamit Nobel Witten/Ruhr Germany, especially Miglyol 812, or MYRITO ~ 318 from Henkel Dusseldorf, Germany.
Component c) is preferably one of the mono- or di-glycerides approved for pharmaceutical use, e.g. a mono~ or di-(C16-C20) fatty acid glyceride, e.g. of stearlc acid or especially of oleic acid. Preferably component c) is glycerol mono-oleate (Monooleinum-Pharmacopoea ~elvetica Sixth Edition).
Naturally when the components a), b) and/or c) present are solid, these should be chosen such that they can .~
D
~13g~
be melted at temperatures at which the peptide is stable.
Such components include, for example, glycerol mono-stearate and glycerol di-stearate.
The preferred total concentration of component a) and/or component b) and/or component c) present in the pharmaceutical compositions according to the invention, as well as the weight ratio of individual components when two or more of these are present, will natuxally depend, ~ , on the particular component(s) used, and in partlcular on the solvent/solubilizing effect thereof, the particular mono-cyclic peptide used, the concentration of mono-cyclic peptide desired in the final composition and the solvent/solubilizing effect of any further pharmaceu-tical excipients present. In general the preferred welght ratio of component a), b) and/or c) to peptide is 10 parts ln total of the component (or components) to 0.2 to 10 parts of peptide,or more preferably 1 to 10 parts by weight of peptide, and conveniently from 1 to 7 parts by weight of peptide.
When components a) and b) are present, without component c), the weight ratio of component a) to com-ponent b) may be, e.gl from 1:1 to 1:2.
When component c) is present with component a) or b), the weight ratio of component c) to component a) or b) may be, e.g./ from 2:1 to 1:2.
When components a), b) and c) are all present, conven-9~
_ 7 - 100-4983 lently they are present in a weight ratlo of about 1:1:1.
The pharmaceutical compositions of the invention may be made by mixing a pharmacologically active mono-cyclic peptide with the liquid carrier comprising component a) and/or b) and/or c) as deflned above.If the o~nent a), ,, . .: , b) or c) is solid~temperatures up to about 70C may be used, to produce a liquid melt in which the active agent may be dissolved in. The composition may be cooled and then, for example, ground.
The pharmaceutical compositions may be formulated in conventional manner, if desired with further pharma-ceutlcal excipients, into forms suitable for oral or parenteral administration. Preferably they are in liquid form.
Examples of preferred compositions are:
a) Solutions for drlnking, e.g. Example 1 herelnafter, b) Emulsions for drinking, c) Injection solutions, e.g. Examples 2 and 4 hereinafter, d) Solutions contained in capsules, e.g. Example 6 herein-after, e) Pellets for oral administration.
The modes of administratlon are preferably intra-muscular and subcutaneous administration or more preferably oral administration. In particular when component b) is present, the pharmaceutical composition is preferably used for parenteral administration.
i~9~, The pharmaceutical compositions acco'rding to the invention may be formulated with or without further exi-pients.
In particular solubilizing a~ents and solvents may be present in a concentration of up to 60~ of the total com-position, if desired, in order to attain a satisfactory concentration of peptide.
i) Ethanol may be used as a further solubilizing agent/
solvent, particularly when the component a), b) or c) pre-sent is in solid form. The ethanol content by weight maybe''for example 2 to 5~ for parenteral compositions and 1 to 20% for oral compositions, calculated on the total compo-sitio~. ' ii) For a parenteral composltion, an alternative further solubilizin~ agent/solvent is a benzoic acid benzyl ester.
This may be present ~t from 5 to~40%~of by weight of the total composition.
iii) A vegetable oil, such as olive oil or co~n oil, may be present in both oral and parehteral compositions as a vehicle. The vegetable oil content by weight may be for example from 35 to 60 %, calculated on the total composition.
iv) For emulsions for drinking, preferably agent a) and/or c) as defined above is present as well as a lecithin such as soya lecithin. Such emulsions may contain from 20% to 80% by weight water and contain eth~anol as a solubilizing agent / solvent.
..._._ ~
v) For oral pellets, it is preferred to use a solid or semi-solid component a), b) or c), espec:ially component c). Colloidal silicic acid, sugar, and microc~ystalline cellulose are sultable excipients.
The properties of the compositions according to the invention may be determined in conventional manner. The sta bility of solutions particularly against crystallization-out of the active agent may be determined using known tests.
Tolerability of injection forms may be de~ermined by ob-serving the extent of bleeding and inflammations after in-jection, e.g. into thighs of rabbits and rhesus monkeys, andthe time taken for these to heal, as well as by using other usual tolerability tests.
The ~sorption of the pharmacologically active pep-tide, e.g rapid onset of a satisfactory concentration of the peptide in the blood, and a high total absorption of the peptide over 24 hours, is indicated in standard tests.
In one test a pharmaceutical composition according to the invention is administered to rabbits, rats, dogs or rhesus monkeys orally, intramuscularly or subcutaneously, at a dose of from 2 to 600 mg/kg animal body weight of active peptide. Blood serum samples and urine samples are taken at regular intervals thereafter, e.g. every hour, and are analysed for the concentration of peptide therein in con-ventional manner.
For example the pharmacological activity in a sample may be ascertained in conventional manner according to known tests. In the case of cyclosporin A the effect of the peptide present in inhibiting lymphocyte proliferation may be ascer-tained. ~'hus the blood serum is collected at regular inter-vals after administration, and is added at a concentration of from 0.3 to 10~ to a mouse in vitro spleen oell--suspension in whlch lymphocyte proliferation is induced by Concavalin A over a 72 hour culture period. 3H-thymidine is then added and the thymidine incorporation after r~ 24 hours ls mea8ured to indicate the lymphocyte proliferation.
If desired,the peptide may be administered in radio-active form. For example in the case of the cyclosporins, in one experiment 100 mg of H-labelled cyclospor~n A (pre-pared hy cultivation of the known strain Tolypocladium inflatum Gams NRRL 8044 in the presence of methionine marked wlth tritlum in the SCH3 group thereofJ contained in a phar-maceutical composition according to the invention in the form of a drinking solution, or in a capsule,is administered perorally, or in the form of an injection solution is admini-stered intramuscularly, to male bea~le dogs. Blood samplesare obtained from each dog every 5 minutes after admini-"
11;~9~
_ 11_ 100-4983 stration up to 1 hour after administration and thereafter every hour thereafter up to 8 hours after ad~inistration.
The urine is collected also. Determination of the radio-activity in the blood and in the urine indicates the peptide absorption.
The amount of peptide to be administered in the pharmaceutical compositions according to the invention wlll naturally depend upon the mode of administration, the effect desired and the condition to be treated.
In general the amount of peptiae to be administered in a pharmaceutical composition accoxding to invention will be of the same order to that administered by the same route in other pharmace~tical compositions.
In the case of the cyclosporins, the amounts to be 15 adm~nistered for a therapeutically effective amount are well-known, When using compositions according to the in-vention a dally dose of from about 3 mg/kg to about 50 mg/kg i~ indicated in order to treat chronic inflammations or to provoke an immunosuppressive effect.
The following examples illustrate the invention.
All temperatures are in degrees Centigrade.
11;~9~7 _ 12 - 100-4983 . .
EXAMPLE 1: Drink Solution ~ _ _ _ _ _ _ 200 mg of cyclosporin A are dissolved on stirring in 1 ml of a mixture of Labrafil M 1944 CS and ethanol (parts by weight 40:15) at 25. 0.4 ml of olive oil or corn oil are added. The resultant mixture is filtered and filled into a small vial.
The final solution contains for every 10 parts by weight of Labrafil; 3 parts by weight of cyclosporin A, 3 parts by weight of ethanol and 5 parts by weight of olive 10 oil or corn oil.
EXAMPLE 2: Parenteral forms for i.m. and s.c.administr~tion 100 mg of cyclosporin A are dissolved on stirring in a mixture of 40 mg ethanol and 0.5 ml Miglyol 812 at 25C~ The mixture is finally made up to 1 ml with Miglyol 15 812 and filled under sterile conditions into ar~ ampoule.
The final solution contains for every 10 part:s by weight of Miglyol 812, 1 part by weight of cyclosporin A.
EXA~IPLE 3: Parenteral forms for i.m. and s.c. administratinn _ 100 mg of cyclosporin A are dissolved on stirring 20 in a mixtuxe of 40 mg ethanol, 100 mg Labrafil M 1944 CS
and 200 mg Miglyol 812 at 25.~ The resulting mixture is made up to 1 ml with olive oil and iilled under sterile conditions into an ampoule.
The final solution contains for every 10 parts by 25 weight of Miglyol 812, 5 part~ ky weight each of cyclos-porin A and Labrafil and 25 parts by weight of olive oil.
. .
il;~9~
_ 13 _ 100-49B3 EXAMPLE 4: Parenteral form for i.m.and s.c. admlnistration 200 mg of cyclosporin A are dissolved in a mixture of 400 mg benzoic acid benzyl ester and 0.3 ml Miglyol 812 at 25. The resultant mixture is made up to 1 ml with Miglyol 812 and fllled under sterile conditions-into an ampoule.
The final solution contains for every 10 parts by weight of Miglyol 812, 6 parts by weight of cyclosporin A.
EX~MPLE 5: Parenter_1 form for i.m. and_s.c.ad~inistratio_ 200 mg of cyclosporin A are dissolved on stirring in a mixture of 50 mg ethanol, 300 mg Labrafil M 1944 CS and 0.3 ml' Miglyol 812 at 25. The resultant solutlon is made up to 1 ml with Miglyol 812 and filled under sterile condi-tions into an ampoule.
The final solution contains for every 10 part~ by weight of Miglyol 812, 7 parts by weight of Labrafil and 5 parts by weight of cyclosporin A.
EXAMPLE 6: Capsules for oral adm_nistration 200 mg of cyclosporin A are dissolved on stirring in a mixture of 600 mg glycerol mono-oleate and 30 mg ethanol at 30. The final solution is encapsulated in a soft gelatine capsule.
Ca~sules for oral administration 400 mg of cyclosporin A are dlssolved on stirring in 600 mg glycerol mono-oleate at 40, and encapsulated ln a soft gelatine capsule.
Claims (18)
1. A pharmaceutical composition comprising a cyclosporin as active ingredient and a carrier comprising at least one of the following components:
a) a trans-esterification product of a natural or hydrogenated vegetable oil triglyceride and a polyalkylene polyol;
b) a saturated fatty acid triglyceride; and c) a mono- or di-glyceride.
a) a trans-esterification product of a natural or hydrogenated vegetable oil triglyceride and a polyalkylene polyol;
b) a saturated fatty acid triglyceride; and c) a mono- or di-glyceride.
2. A pharmaceutical composition according to claim 1, wherein the active ingredient is selected from the group consisting of cyclosporin A, dihydrocyclosporin C, cyclosporin D and dihydrocyclosporin D.
3. A pharmaceutical composition according to claim 1, wherein the carrier comprises component a) together with x) a vegetable oil and y) ethanol.
4. A pharmaceutical composition according to claim 3, wherein the active ingredient is cyclosporin A.
5. A pharmaceutical composition according to claim 3, wherein component a) is a trans-esterification product of two molar parts of a natural vegetable oil tri-glyceride and one molar part of a polyethylene glycol of MW 200 to 800.
6. A pharmaceutical composition according to claim 3, wherein component a) is a trans-esterification product of two molar parts of kernel oil and one molar part of a polyethylene glycol of MW 200 to 800.
7. A pharmaceutical composition according to claim 3, wherein component a) is a polyoxyethylated kernel oil mixture, having a density of D20 = 0.940-0.965, an acid number 2, an iodine number = 60-90, a saponification number = 145-175 and a hydrophilic-lipophilic balance (H.L.B.) = 4.
8. A pharmaceutical composition according to any one of claims 2, 3 or 7, wherein x) is olive oil or corn oil.
9. A pharmaceutical composition according to any one of claims 2, 3 or 7, wherein x) is olive oil.
10. A pharmaceutical composition according to any one of claims 2, 3 or 7, wherein the ratio of component a) to cyclosporin is 10:0.2 to 10 parts by weight.
11. A pharmaceutical composition according to any one of claims 2, 3 or 7, wherein the ratio of component a) to cyclosporin is 10:1 to 7 parts by weight.
12. A pharmaceutical composition according to any one of claims 2, 3 or 7, wherein x) and y) together are present in an amount of up to 60% by weight based on the total weight of the composition.
13. A pharmaceutical composition according to any one of claims 2, 3 or 7, comprising at least 35% by weight of x), based on the total weight of the composition.
14. Composition according to claim 3, formulated as solution for oral administration.
15. Composition according to claim 14, comprising 1 to 20% by weight of y), based on the total weight of the composition.
16. Composition according to claim 3, formulated as solu-tion for parenteral administration.
17. Composition according to claim 16 for i.m. or s.c.
administration.
administration.
18. Composition according to claim 16 or 17, comprising 2 to 5% by weight of y), based on the total weight of the composition.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH2461/78 | 1978-03-07 | ||
CH246178A CH636013A5 (en) | 1978-03-07 | 1978-03-07 | More readily absorbable pharmaceutical composition |
CH8634/78 | 1978-08-14 | ||
CH863478 | 1978-08-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1139667A true CA1139667A (en) | 1983-01-18 |
Family
ID=25690510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000322853A Expired CA1139667A (en) | 1978-03-07 | 1979-03-06 | Galenical compositions |
Country Status (27)
Country | Link |
---|---|
US (1) | US4388307A (en) |
JP (1) | JPS54132223A (en) |
AR (1) | AR223667A1 (en) |
AT (1) | AT375828B (en) |
AU (1) | AU528714B2 (en) |
CA (1) | CA1139667A (en) |
CY (1) | CY1285A (en) |
DD (1) | DD142149A5 (en) |
DE (1) | DE2907460A1 (en) |
DK (1) | DK154539C (en) |
ES (1) | ES478295A1 (en) |
FI (1) | FI65914C (en) |
FR (1) | FR2419072A1 (en) |
GB (1) | GB2015339B (en) |
HK (1) | HK48585A (en) |
IE (1) | IE48016B1 (en) |
IL (1) | IL56790A (en) |
IT (1) | IT1115038B (en) |
KE (1) | KE3516A (en) |
MY (1) | MY8500134A (en) |
NL (2) | NL187260C (en) |
NO (2) | NO152635C (en) |
NZ (1) | NZ189819A (en) |
PH (1) | PH15159A (en) |
PT (1) | PT69309A (en) |
SE (1) | SE445174B (en) |
SG (1) | SG14785G (en) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE54936B1 (en) * | 1980-02-14 | 1990-03-28 | Sandoz Ltd | A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
DE3224619A1 (en) * | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Oral pharmaceutical composition |
US4525339A (en) * | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
EP0127426A1 (en) * | 1983-05-23 | 1984-12-05 | Takeda Chemical Industries, Ltd. | Percutaneous pharmaceutical compositions for external use |
GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
US5474980A (en) * | 1984-10-04 | 1995-12-12 | Monsanto Company | Prolonged release of biologically active somatotropins |
US4727035A (en) * | 1984-11-14 | 1988-02-23 | Mahoney Walter C | Immunoassay for cyclosporin |
US4576645A (en) * | 1984-12-06 | 1986-03-18 | Block Drug Co., Inc. | Whipped gel composition |
JPS61280435A (en) * | 1985-04-04 | 1986-12-11 | Kanji Takada | Lymph orienting preparation of cyclosporin |
US4775659A (en) * | 1985-08-19 | 1988-10-04 | Eli Lilly And Company | Injectable semi-solid formulations |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
US4764381A (en) * | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
US5118493A (en) * | 1986-05-02 | 1992-06-02 | Brigham And Women's Hospital | Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine |
JP2574354B2 (en) * | 1986-05-02 | 1997-01-22 | ブリガム・アンド・ウイメンズ・ホスピタル | Reduced nephrotoxic composition comprising fatty acid-containing components and cyclosporin |
KR880012221A (en) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | Pharmaceutical compositions containing esters or amides as active ingredients |
JP2577049B2 (en) * | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
EP0391909B1 (en) * | 1987-09-03 | 1994-08-17 | The University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
AU620048B2 (en) * | 1987-09-03 | 1992-02-13 | University Of Georgia Research Foundation, Inc., The | Ocular cyclosporin composition |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
HU205010B (en) * | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
DE3830494B4 (en) * | 1987-09-15 | 2006-05-18 | Novartis Ag | Water-soluble monoesters as solubilizers for pharmacologically active substances and pharmaceutical excipients |
ES2033086T3 (en) * | 1988-01-29 | 1993-03-01 | Sankyo Company Limited | A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION. |
CH679119A5 (en) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
KR0148748B1 (en) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
GR1000466B (en) * | 1989-01-28 | 1992-07-30 | Sandoz Ag | Preparation method of novel pharmaceutical forms of cyclosporine |
GB2230440B (en) * | 1989-02-09 | 1993-05-19 | Sandoz Ltd | Novel cyclosporin galenic forms |
US7081445B2 (en) | 1989-02-20 | 2006-07-25 | Novartis Ag | Cyclosporin galenic forms |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
HU208491B (en) * | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
US6262022B1 (en) | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
GB9208712D0 (en) * | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
ATE147619T1 (en) | 1992-05-13 | 1997-02-15 | Sandoz Ag | OPTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN |
DE59310166D1 (en) * | 1992-05-18 | 2001-05-31 | Ciclomulsion Ag | Pharmaceutical preparation containing cyclosporin (s) for intravenous administration and process for its preparation |
US5637317A (en) * | 1992-05-18 | 1997-06-10 | Dietl; Hans | Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same |
CZ278863B6 (en) * | 1992-09-07 | 1994-07-13 | Galena | Medicinal preparations with n-methylated cyclic undecapeptides |
ES2168271T3 (en) | 1992-09-25 | 2002-06-16 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORINS. |
NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
CH686761A5 (en) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Pharmaceutical formulations. |
US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
DE69435104D1 (en) | 1993-09-28 | 2008-07-31 | Scherer Gmbh R P | Production of soft gelatine capsules |
DE4340781C3 (en) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Liquid preparations containing cyclosporin and process for their preparation |
KR0146671B1 (en) * | 1994-02-25 | 1998-08-17 | 김충환 | Cyclosporin-containing powder composition |
NZ270145A (en) * | 1994-03-01 | 1996-08-27 | Lilly Co Eli | Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent |
SE518578C2 (en) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipid-based composition |
WO1996003113A1 (en) * | 1994-07-22 | 1996-02-08 | G.D. Searle & Co. | Self-emulsifying drug delivery system |
CA2231404C (en) | 1994-11-03 | 2009-02-17 | Arzneimittelwerk Dresden Gmbh | Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them |
US5603951A (en) * | 1994-11-09 | 1997-02-18 | Hanmi Pharm. Ind. Co., Ltd. | Cyclosporin-containing soft capsule compositions |
HU215966B (en) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Oral multiple emulsion-preconcentrate containing cyclosporin |
KR0167613B1 (en) * | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | Cyclosporin-containing soft capsule compositions |
KR100239799B1 (en) * | 1995-01-21 | 2000-02-01 | 손경식 | Cyclosporin a solid micelle dispersion for oral administration, the preparation method thereof and its solid dosage form |
US6696413B2 (en) * | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
SE504582C2 (en) * | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyclosporin composition based on an L2 phase |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
WO1997007787A1 (en) * | 1995-08-25 | 1997-03-06 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
DE19544507B4 (en) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin containing preparations |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
KR980008239A (en) * | 1996-07-26 | 1998-04-30 | 김충환 | Cyclosporin-containing pharmaceutical composition |
US5798333A (en) * | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
DE29824679U1 (en) | 1997-01-30 | 2002-03-28 | Novartis Ag | Pharmaceutical compositions |
JP4718653B2 (en) * | 1997-03-12 | 2011-07-06 | アボツト・ラボラトリーズ | Hydrophilic two-component system for administration of cyclosporine |
NZ314702A (en) * | 1997-04-29 | 1998-07-28 | Bernard Charles Sherman | Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent |
CA2285983A1 (en) | 1997-04-29 | 1998-11-05 | Bernard Charles Sherman | Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride |
US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
IN188719B (en) * | 1997-09-08 | 2002-11-02 | Panacea Biotec Ltd | |
US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
KR19990047897A (en) * | 1997-12-05 | 1999-07-05 | 김충환 | Cyclosporine-containing pharmaceutical composition |
US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
US6028067A (en) * | 1997-12-05 | 2000-02-22 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
CN1236813C (en) * | 1998-12-11 | 2006-01-18 | 药品处理公司 | Self-emulsifying compositions for drugs poorly soluble in water |
JP2002534370A (en) | 1998-12-30 | 2002-10-15 | デクセル リミテッド | Dispersible concentrate for delivering cyclosporin |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
JP2003531099A (en) * | 1999-03-24 | 2003-10-21 | エフ エム シー コーポレーション | Pharmaceutical formulations with improved water solubility |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6057289A (en) * | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
EP1273287A1 (en) * | 2000-04-04 | 2003-01-08 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
AU6608701A (en) * | 2000-06-21 | 2002-01-02 | Audit Institute For Medical Services And Quality Assurance Gmbh | Pharmaceutical preparations containing cyclosporines and neutral oils |
MXPA02004900A (en) | 2000-09-18 | 2003-10-24 | Rpg Life Sciences Ltd | Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities. |
OA12619A (en) * | 2001-06-21 | 2006-06-12 | Pfizer Prod Inc | Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. |
WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
AR036852A1 (en) * | 2001-10-19 | 2004-10-06 | Isotechnika Inc | PRE-CONCENTRATED OF A MICROEMULSION OF CYCLOSPORINE ANALOGS, ITS PREPARATION METHOD AND METHODS TO PRODUCE IMMUNOSUPPRESSION |
US20050070468A1 (en) * | 2001-11-21 | 2005-03-31 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
EP1455753A1 (en) * | 2001-12-20 | 2004-09-15 | Bernard Charles Sherman | Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
KR20030065831A (en) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | cyclosporin-containing sustained release pharmaceutical composition |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
GB2391473B (en) * | 2002-08-02 | 2004-07-07 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
GB2391472B (en) * | 2002-08-02 | 2004-12-08 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
KR100507771B1 (en) * | 2002-11-08 | 2005-08-17 | 한미약품 주식회사 | A composition for oral administration of water-insoluble anti-cold drug and a preparation method thereof |
US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
US6979672B2 (en) | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
US20040150061A1 (en) * | 2003-01-30 | 2004-08-05 | Hsin Chung Hsien | Package structure of a photosensor |
JP2006521366A (en) * | 2003-03-28 | 2006-09-21 | シグモイド・バイオテクノロジーズ・リミテッド | Solid oral dosage forms containing seamless microcapsules |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
SG148198A1 (en) | 2003-11-21 | 2008-12-31 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
DE102004038980A1 (en) * | 2004-08-10 | 2006-02-23 | Cognis Deutschland Gmbh & Co. Kg | Anti-fogging agent for plastics |
US20080020018A1 (en) * | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
CN101141953A (en) * | 2005-03-21 | 2008-03-12 | 伊瓦克斯制药有限公司 | Crystallization inhibitor and its use in gelatin capsules |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
JP2009514969A (en) | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | Methods, compositions, and kits for treating medical conditions |
CA2683415C (en) | 2007-04-04 | 2020-12-08 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
BRPI0811538A2 (en) * | 2007-05-04 | 2015-08-11 | Allergan Inc | Use of cyclosporins in the treatment of patients with intraocular lenses. |
GB2451811A (en) | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
TW200932240A (en) * | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
KR20110123739A (en) | 2009-01-08 | 2011-11-15 | 알러간, 인코포레이티드 | Compositions for enhancing nail growth |
US20110009339A1 (en) | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
US9278070B2 (en) | 2009-05-18 | 2016-03-08 | Sigmoid Pharma Limited | Composition comprising oil drops |
MX2011013824A (en) | 2009-07-07 | 2012-01-30 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor. |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
PT2683406T (en) | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anti-cd40 antibodies and uses thereof |
CN103957875A (en) | 2011-10-05 | 2014-07-30 | 阿勒根公司 | Compositions for enhancing nail health |
BR112014008172A2 (en) | 2011-10-05 | 2017-04-18 | Allergan Inc | nail health enhancing compositions |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
KR20170102223A (en) | 2014-11-07 | 2017-09-08 | 시그모이드 파마 리미티드 | Compositions comprising cyclosporin |
CN116063481A (en) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | Humanized anti-CD 40 antibodies and uses thereof |
JPWO2017047299A1 (en) * | 2015-09-15 | 2017-12-21 | 富士フイルム株式会社 | Liquid composition for injection |
JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1274354A (en) * | 1956-03-10 | 1961-10-27 | Surfactants obtained from triglycerides and polyethylene glycol | |
GB1110875A (en) * | 1964-12-11 | 1968-04-24 | Glaxo Lab Ltd | Compositions containing procaine penicillins |
FR94740E (en) * | 1967-10-25 | 1969-10-24 | Rhone Poulenc Sa | New cyclopeptides and their preparation. |
NL167323C (en) * | 1970-09-26 | 1981-12-16 | Organon Nv | PROCESS FOR PREPARING A PSYCHOPHARMACOLOGICAL PREPARATION. |
ES396746A1 (en) * | 1971-11-06 | 1974-12-01 | Gallardo Antonio Sa | New procedure for the manufacture of suitable stable suspensions for antibiotics. (Machine-translation by Google Translate, not legally binding) |
CH574247A5 (en) * | 1972-02-17 | 1976-04-15 | Ciba Geigy Ag | Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity |
JPS4891218A (en) * | 1972-03-06 | 1973-11-28 | ||
AR207116A1 (en) * | 1973-03-28 | 1976-09-15 | Ciba Geigy Ag | PROCEDURE TO PREPARE NEW DOTRIACONTAPEPTIDOAMIDES |
DE2455859C2 (en) * | 1973-12-06 | 1983-12-15 | Sandoz-Patent-GmbH, 7850 Lörrach | The antibiotic Cyclosporin A (S 7481 / F-1), its manufacture and use |
GB1547164A (en) * | 1975-08-14 | 1979-06-06 | Beecham Group Ltd | Veterinary compositions |
CH614931A5 (en) * | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
DE2555481C3 (en) * | 1975-12-10 | 1985-10-03 | Sandoz-Patent-GmbH, 7850 Lörrach | Production of stable drop solutions of hydrogenated ergot alkaloids |
DE2819094A1 (en) * | 1977-05-10 | 1978-11-23 | Sandoz Ag | CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING |
-
1979
- 1979-02-26 DE DE19792907460 patent/DE2907460A1/en active Granted
- 1979-02-26 FI FI790640A patent/FI65914C/en not_active IP Right Cessation
- 1979-02-26 SE SE7901683A patent/SE445174B/en not_active IP Right Cessation
- 1979-02-27 NO NO790661A patent/NO152635C/en unknown
- 1979-02-27 FR FR7904989A patent/FR2419072A1/en active Granted
- 1979-02-27 IT IT48152/79A patent/IT1115038B/en active Protection Beyond IP Right Term
- 1979-02-28 DK DK086079A patent/DK154539C/en not_active IP Right Cessation
- 1979-03-02 NL NLAANVRAGE7901703,A patent/NL187260C/en active Protection Beyond IP Right Term
- 1979-03-02 CY CY1285A patent/CY1285A/en unknown
- 1979-03-02 GB GB7907395A patent/GB2015339B/en not_active Expired
- 1979-03-05 NZ NZ189819A patent/NZ189819A/en unknown
- 1979-03-05 AT AT0163779A patent/AT375828B/en not_active IP Right Cessation
- 1979-03-05 PT PT69309A patent/PT69309A/en unknown
- 1979-03-05 ES ES478295A patent/ES478295A1/en not_active Expired
- 1979-03-05 IL IL56790A patent/IL56790A/en unknown
- 1979-03-06 CA CA000322853A patent/CA1139667A/en not_active Expired
- 1979-03-06 PH PH22254A patent/PH15159A/en unknown
- 1979-03-06 AU AU44862/79A patent/AU528714B2/en not_active Expired
- 1979-03-06 DD DD79211409A patent/DD142149A5/en not_active IP Right Cessation
- 1979-03-07 AR AR275732A patent/AR223667A1/en active
- 1979-03-07 JP JP2722879A patent/JPS54132223A/en active Granted
- 1979-08-08 IE IE704/79A patent/IE48016B1/en not_active IP Right Cessation
-
1982
- 1982-02-09 US US06/347,276 patent/US4388307A/en not_active Expired - Lifetime
-
1985
- 1985-02-27 SG SG147/85A patent/SG14785G/en unknown
- 1985-03-22 KE KE3516A patent/KE3516A/en unknown
- 1985-06-20 HK HK485/85A patent/HK48585A/en not_active IP Right Cessation
- 1985-12-30 MY MY134/85A patent/MY8500134A/en unknown
-
1993
- 1993-07-02 NL NL930135C patent/NL930135I1/en unknown
-
1994
- 1994-12-28 NO NO1994028C patent/NO1994028I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1139667A (en) | Galenical compositions | |
US5589455A (en) | Cyclosporin-containing soft capsule compositions | |
KR100894130B1 (en) | Pharmaceutical compositions comprising cyclosporins | |
FI116199B (en) | High bio:availability cyclosporin compsn. for oral admin. - comprises mixt. of mono-, di- and tri- glyceride(s), surfactant, and solvent | |
US6063762A (en) | Cyclosporin-containing microemulsion preconcentrate composition | |
KR100257841B1 (en) | Cyclosporin-containing pharmaceutical composition | |
JP4073641B2 (en) | New cyclosporine preparation | |
FR2643262A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON CYCLOSPORINS | |
EP0813876B1 (en) | Cyclosporin-containing soft capsule preparations | |
US5958876A (en) | Cyclosporin-containing pharmaceutical compositions | |
SA90100287B1 (en) | Pharmaceutical capsules contain ranitidine | |
WO1997026003A1 (en) | Cyclosporin formulation | |
US6028067A (en) | Cyclosporin-containing microemulsion preconcentrate composition | |
PL188500B1 (en) | Preparations in the form of soft capsules containing cyclosporin | |
HU182920B (en) | Process for preparing stable pharmaceutical compositions containing cyclosporin | |
KR100300251B1 (en) | Cyclosporine-containing pharmaceutical composition | |
FR2726470A1 (en) | COMPOSITION BASED ON INTERFERON | |
KR19980073479A (en) | Cyclosporine-containing soft capsules | |
KR100256007B1 (en) | Pharmaceutical compositions comprising cyclosporins | |
MXPA00005507A (en) | Cyclosporin-containing microemulsion preconcentrate composition | |
KR19990047897A (en) | Cyclosporine-containing pharmaceutical composition | |
MXPA99008438A (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |